Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at 50th ASH Annual Meeting and Exposition by NIH investigators

Biopharmaceutical company Kiadis Pharma announces the presentation of results obtained so far in a physician initiated clinical study for ATIR™ led by Dr. Stephan Mielke* and Dr. John Barrett* of the National Heart, Lung, and Blood Institute (NHLBI), a department of the National Institutes of Health (NIH), at the 50th ASH Annual Meeting and Exposition to be held on December 6 - 9, 2008 at the Moscone Convention Center in San Francisco, USA.

Title poster:  “Selective Allodepletion by TH9402-Mediated Photosensitization Results in Early Full Donor T Cell Reconstitution in the Absence of High-Grade, Acute GvHD and Is Associated with Favorable Outcome after HLA Matched Sibling SCT for Hematologic Malignancies”

Abstract:  1168
Session Name: Clinical Transplantation - Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution Poster I 
Date: Saturday, December 6, 2008
Presentation Time: 5:30 PM - 7:30 PM
Location: Moscone Center, Hall A
Poster Board no.: I-273

About ATIR™
Kiadis Pharma is developing ATIR™ for the prevention of acute Graft versus Host Disease (GvHD) and early immune reconstitution following an allogeneic bone marrow transplantation using mismatched donors. ATIR™ selectively eliminates immune cells that could otherwise attack the patient’s body after an allogeneic bone marrow transplantation and cause acute (GvHD). Because the risk for acute GvHD is eliminated, no immune suppressants have to be used post transplantation allowing early immune reconstitution in these patients reducing the risk of opportunistic infections. Eliminating the risk of acute GvHD and early immune reconstitution can improve the outcome of current allogeneic transplantations and, moreover, allows the use of a mismatched donor enabling virtually all eligible patients to find a donor. Kiadis Pharma’s ATIR™ product is under evaluation in two “mismatched donor” trials. The clinical phase II study by the NIH has extended the use of ATIR™ in HLA-matched transplantations.

About Kiadis Pharma
Kiadis Pharma is an oncology focused biopharmaceutical development company with three products in different phases of clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address high-unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures performed in blood cancer patients. Kiadis Pharma is headquartered in Amsterdam, The Netherlands. For more information about Kiadis Pharma, please visit www.kiadis.com

*Note
Dr. John Barrett is the Chief of the Allotransplant Section at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) in Bethesda, MD, USA, where the trial is being performed. Dr. Stephan Mielke, who initiated this study as principal investigator at the NHLBI, is currently working at the Julius-Maximilians University of Würzburg, Germany and continues as the lead associate investigator on the protocol.